Worse COVID-19 outcomes in patients with systemic lupus erythematosus are driven by comorbidities, demographics and untreated or active disease, according to data published in the Annals of the Rheumatic Diseases.The researchers added that patients using low-dose glucocorticoids also demonstrated more severe COVID-19 outcomes.